Untreated cases drive sleep market, report says
NEW YORK – Undiagnosed cases and new devices will drive growth in the global sleep apnea device market, a new Kalorma report says. In the U.S., 18 million are affected by sleep apnea in any given year, the report says, while another 10 million are undiagnosed. “Sleep apnea is very common,” said study author Mary Ann Crandall. “Yet because of the lack of awareness by the public and healthcare professionals, the vast majority remain undiagnosed and therefore untreated.” The report predicts an influx of device alternatives in the future as large companies expand their offerings through acquisitions. For example, ResMed acquired Narval SA, which makes a mandibular repositioning device, and Philips Respironics purchased Aspire Medical, which makes an implant to treat sleep apnea. The market grew from $3.6 billion in 2011 to $4.2 billion in 2013, according to the report.